高危HR+/HER2-早期乳腺癌患者在接受内分泌治疗联合或不联合哌柏西利的随机PENELOPEB研究中的患者报告结局
PENELOPEB研究比较高危HR+/HER2-早期乳腺癌患者在新辅助治疗后接受1年哌柏西利联合标准内分泌治疗与单纯内分泌治疗的患者报告结局。哌柏西利组与安慰剂组总体健康状况/生活质量均较高,安慰剂组略高;哌柏西利组疲劳评分略高;差异无临床意义。
要点
- 哌柏西利组与安慰剂组总体健康状况/生活质量均较高,安慰剂组略高(最小二乘均值差0.82,p<0.001)。
- 哌柏西利组疲劳评分高于安慰剂组(均值[标准差]:30.3[23.8] vs 28.3[22.7];p<0.001)。
- FA13躯体、认知和情感疲劳子量表两组间无统计学显著差异。
核心结论
- 两组患者报告的整体生活质量和疲劳均无实质性变化,总体健康状况、躯体功能和疲劳的轻微差异在统计学上偏向安慰剂组,但未达到临床意义阈值。
研究设计与样本
- 随机PENELOPEB研究的事后分析,比较哌柏西利组(n=631)与安慰剂组(n=619)的患者报告结局。
- 患者接受哌柏西利125 mg/天或安慰剂口服,每4周用药3周,共13个周期,联合内分泌治疗。
- 采用EORTC QLQ-C30及其BR23和FA13模块、GAD7情绪问卷和EQ-5D工具评估生活质量。
- 使用重复测量混合效应模型评估患者报告结局差异、随时间变化及治疗与时间交互作用。
主要发现
- 1250例患者中924例(73.9%)完成基线及至少一次基线后所有患者报告结局工具问卷。
- EORTC QLQ-C30总体健康状况/生活质量在两组均较高(均值[标准差]:哌柏西利组70.1[19.3],安慰剂组71.4[18.8]),安慰剂组略高(最小二乘均值差0.82,p<0.001)。
- 哌柏西利组报告疲劳更高(均值[标准差]:30.3[23.8] vs 安慰剂组28.3[22.7];p<0.001)。
- FA13躯体、认知和情感疲劳子量表两组间无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PENELOPEB trial investigating efficacy and safety of additional 1-year post-neoadjuvant palbociclib to standard endocrine therapy (ET) high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer patients failed to improve invasive disease-free survival (iDFS). This analysis compared patient-reported outcomes (PROs) between treatment groups. PATIENTS AND METHODS: Patients received 13 cycles of palbociclib 125 mg/day (n = 631) or placebo (n = 619) orally for 3 out of 4 weeks + ET. European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30), its breast cancer (BR23) and fatigue (FA13) modules, mood questionnaire GAD7 and European Quality of Life 5 Dimensions (EQ-5D) instruments were used for the assessment of quality of life (QoL). Repeated-measures mixed-effects models were used to evaluate differences in PRO, changes of PRO over time, and treatment-by-time interactions. RESULTS: 924 of 1250 patients (73.9%) completed baseline and at least one post-baseline questionnaire of all PRO instruments. General health status (GHS)/QoL based on EORTC QLQ-C30 was high in both arms (mean [SD]: palbociclib 70.1 [19.3], placebo 71.4 [18.8]) and was slightly higher in the placebo arm (LeastSquare mean difference: 0.82, p < 0.001). Higher fatigue was reported in the palbociclib arm (mean [SD]: 30.3 [23.8] vs. placebo 28.3 [22.7]; p < 0.001). No statistically significant differences were observed among FA13 physical, cognitive, and emotional fatigue subscales. CONCLUSION: Patient-reported global QoL and fatigue did not substantially change in both treatment arms. Slight differences in GHS, physical functioning, and fatigue favored the placebo arm statistically without achieving clinically meaningful thresholds.
引用
- García-Sáenz JA, Marmé F, Untch M, et al. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study. Eur J Cancer. 2023. PMID: 38000218. doi:10.1016/j.ejca.2023.113420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。